Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-96.14%
operating margin TTM
-107.26%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -3.78 |
| peg ratio | -0.09 |
| price to book ratio | 1.23 |
| price to sales ratio | 3.64 |
| enterprise value multiple | -6.26 |
| price fair value | 1.23 |
profitability ratios | |
|---|---|
| gross profit margin | 94.77% |
| operating profit margin | -107.26% |
| pretax profit margin | -92.74% |
| net profit margin | -96.14% |
| return on assets | -16.57% |
| return on equity | -36.1% |
| return on capital employed | -28.78% |
liquidity ratio | |
|---|---|
| current ratio | 2.40 |
| quick ratio | 2.40 |
| cash ratio | 1.43 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.84 |
| days of payables outstanding | 1,587.94 |
| cash conversion cycle | -1,587.10 |
| receivables turnover | 437.12 |
| payables turnover | 0.23 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.10 |
| debt equity ratio | 0.19 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.16 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 0.98 |
cash flow ratios | |
|---|---|
| free cash flow per share | 0.62 |
| cash per share | 6.06 |
| operating cash flow per share | 0.68 |
| free cash flow operating cash flow ratio | 0.91 |
| cash flow coverage ratios | 0.98 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 10.53 |
Frequently Asked Questions
When was the last time Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported earnings?
Monte Rosa Therapeutics, Inc. (GLUE) published its most recent earnings results on 07-11-2024.
What is Monte Rosa Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)'s trailing twelve months ROE is -36.1%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Monte Rosa Therapeutics, Inc. (GLUE) currently has a ROA of -16.57%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did GLUE's net profit margin stand at?
GLUE reported a profit margin of -96.14% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is GLUE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.40 in the most recent quarter. The quick ratio stood at 2.40, with a Debt/Eq ratio of 0.19.